InSite Vision to Present at the 13th Annual BIO CEO & Investor Conference

ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, announced today that Timothy Ruane, Chief Executive Officer, will present a corporate overview at the upcoming BIO CEO & Investor Conference. The conference is being held February 14-15, 2011 at the Waldorf Astoria hotel in New York City.

Mr. Ruane’s presentation is scheduled for Tuesday, February 15, 2011 at 1:00 pm ET. Mr. Ruane will discuss InSite’s commercial products and emerging pipeline, including a presentation of previously undisclosed Phase 3 efficacy and safety data for AzaSite Plus (ISV-502) and ISV-305.

The presentation will also be webcast and available on the Investor Relations page of the company's website at The presentation will be archived for replay at the same address one hour after conclusion of the live event for a period of 30 days.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes AzaSite Plus (ISV-502) and ISV-305 for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit


InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
[email protected]
BCC Partners
Michelle Corral, 415-794-8662
Media/Investor Inquiries

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Technology  Software  Health  Biotechnology  Optical  Pharmaceutical